It is now established that activation of two vasopressin receptors located in the circulation, V1-R and V2-R, causes opposite vascular eff ects; that is, vasoconstriction and vasodilation, respectively. Hence, Rehberg and colleagues examined whether a V2-R blocker may prevent vasodilation and help maintain cardiovascular homeostasis during septic shock [1] .
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Vasopressin has long been recognized to have very potent vasoconstrictor action in isolated vascular preparations, but when infused in vivo under normal conditions vasopressin increases blood pressure only modestly at best. In addition, development of vasopressin's vasocon striction blockers a few decades ago showed them to be ineff ective in lowering the blood pressure of most forms of hypertension. Unsurprisingly, therefore, there was little interest in vasopressin's vascular action until our report that some patients with prolonged vasodilatory shock had inappropriately low plasma vasopressin levels and that administration of exogenous hormone quickly restored blood pressure [2] .
Like most hormones involved in blood pressure and extracellular fl uid control, however, vasopressin has several receptors that regulate diff erent functions. Vasopressin's vasoconstriction action is mediated by the V1a receptor, V1a-R, located in vascular smooth muscle. Th e second vasopressin receptor (V2-R) is abundantly present in the collecting duct, where it mediates the hormone's antidiuretic action. While the role of this receptor outside the kidney is less well understood, it is known to be located in the endothelium and pharmacological studies have shown that its specifi c activation in the circulation induced vasodilation and hypotension and the release of the coagulation factors VIIIc and von Willebrand factor. Th ese fi ndings suggest that the use of vasopressin as a pressor in clinical medicine could be made safer and perhaps more eff ective using selective activation of V1a-R or blockade of V2-R.
In this regard, in two recent studies where a selective V1a-R agonist was compared with exogenous vasopressin during septic shock, the former was found to be of superior benefi t than the natural hormone, which, needless to say, stimulated both V1a-R and V2-R [3, 4] . Th ese provocative experiments suggested that administration of exogenous vasopressin to maintain blood pressure in septic shock is complicated by stimulation of receptors with confl icting function. Moreover, because -as in the early phase of sepsis -endogenous plasma vasopressin can reach exceedingly high levels [5] , it is also possible that stimulation of the V2-R by endogenous hormone could in fact contribute to the disease process.
Accordingly, Rehberg and colleagues examined the hypothesis that administration of a V2-R-specifi c blocker during the early phase of septic shock may have a benefi cial eff ect (that is, be more eff ective in maintaining cardiovascular homeostasis than placebo) or may be superior to administration of exogenous vasopressin. Briefl y, they induced septic shock in sheep by intraperitoneal injection of feces and, upon development of hypotension, animals were randomly assigned to receive vehicle, vasopressin or the V2-R antagonist [1] contains much interesting data, but we focus on its more important results. First, the amount of norepinephrine needed to maintain mean arterial pressure was no diff erent among the groups. Th ere was a statistically signifi cant increase, however, in the survival time for the group of animals receiving the V2-R blocker when compared with those receiving placebo or receiving vasopressin. In concordance with this fi nding, the animals treated with the V2-R antagonist displayed less severe lactic acidosis as well as oxidative stress. Finally, the authors made the intriguing observation that the plasma levels of vaso pressin were markedly reduced in the animals receiving the V2-R blocker.
What are we to make of these observations? Since the dose of norepinephrine needed to maintain blood pressure was similar in all groups, we can conclude that in the early phase of septic shock -when plasma levels of vasopressin were endogenously increased (in the animals receiving placebo) or increased by administration of exogenous hormone -a potential vasodilator action of the V2-R is unlikely to have contributed to determine the blood pressure. Had this been the case, the animals receiving the V2-R blocker would have required less norepinephrine. Nonetheless, this group of animals had longer survival as well as metabolic evidence of less severe disease. Th e explanation for this benefi t is a matter of speculation: improved cardiovascular homeostasis (higher left ventricle stroke index and central venous and pulmonary artery occlusion pressures with V2-R blockade were observed); inhibition of vein dilatation; prevention release of coagulation factors thereby retarding development of capillary thrombosis; and reduction of endo thelial nitric oxide release with diminution of reactive oxygen species.
Concerning the very interesting fi nding that plasma vasopressin levels dramatically decreased in animals with V2-R blockade, as Rehberg and colleagues note, in vitro experiments [6] and in vivo experiments [7] indicate that vasopressin has a positive feedback on its own secretion that appears to be V2-R mediated. Th is intriguing fi nding needs confi rmation.
In sum, this work is a valuable addition to the emerging literature on the mechanisms of action of vasopressin during septic shock and highlights for the fi rst time a role of V2-R. Th is work makes it clear that future research on vasopressin's role in septic shock needs to take into account the precise vasopressin receptors that are stimulated and/or inhibited.
